Table 1 Patients and treatment characteristics
N = 110 | n | % |
|---|---|---|
Gender | ||
M | 98 | 89.1% |
F | 12 | 10.9% |
Age | ||
≤ 60 | 60 | 54.5% |
>60 | 50 | 45.5% |
Histology | ||
Adenocarcinoma | 7 | 6.4% |
Squamous cell | 103 | 93.6% |
Tumour site | ||
Upper third | 41 | 37.3% |
Middle third | 50 | 45.5% |
Lower third | 19 | 17.3% |
Staging (CT or EUS) (n = 102) | ||
I | 9 | 8.8% |
IIA | 31 | 30.4% |
IIB | 15 | 14.7% |
III | 41 | 40.2% |
IV | 6 | 5.9% |
Radiation (Gy) | ||
<50.4 | 3 | 2.7% |
50.4 | 58 | 52.7% |
>50.4 | 49 | 44.5% |
Chemotherapy | 95 | 86.4% |
Cisplatin + Fluorouracil | 91 | 82.7% |
Other* | 4 | 3.7% |
Surgery | 16 | 14.5% |
For recurrence | 3 | 2.7% |
For remaining dysphagia | 2 | 1.8% |
Patient’s wish after open discussion with his surgeon, after chemoradiation | 11 | 10% |
Endoprosthesis | 10 | 9.1% |
Before radiation | 9 | 8.2% |
After radiation | 1 | 0.9% |
Dilatation | 16 | 14.5% |
Before radiation | 14 | 12.7% |
After radiation | 2 | 1.8% |